The results of a new study into side effects of gadolinium MRI contrast agents indicates that patients undergoing dialysis are at 77 fold higher risk of contracting nephrogenic systemic fibrosis…
An FDA advisory committee is planning to review a decision by the agency to place the same warning on all gadolinium-based MRI contrast agents about the risk of nephrogenic systemic…
The FDA has approved a new gadolinium-based contrast agent, Vasovist Injection, which is the first imaging agent approved for use during Magnetic Resonance Imaging (MRA) examinations.
Lawyers for the plaintiffs and lawyers for the manufacturers of gadolinium based MRI contract agents, have filed a joint list of 193 NSF lawsuits which are eligible to be among…
Lawyers involved in the federal litigation over gadolinium-based contrast agents, which have been linked to the development of a debilitating condition known as Nephrogenic Systemic Fibrosis, are scheduled to meet…
Gadolinium based contrast agents used during MRI and MRA tests could cause nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy (NFD) for individuals with moderate to severe kidney…
